# Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

> **NCT02598310** · PHASE2 · TERMINATED · sponsor: **Osaka Medical College** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Estrogen Receptor Negative Neoplasm
- HER-2 Positive Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02598310
- **Lead sponsor:** Osaka Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598310, "Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02598310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*